Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Oppenheimer maintained its Outperform rating and $140.00 price target on Abbott Labs (NYSE:ABT) Monday, citing increasing optimism about the company’s Volt system and upcoming glucose-ketone monitoring technology. The target aligns closely with InvestingPro’s Fair Value calculation for the healthcare giant, which boasts a market capitalization of $230 billion and maintains a solid financial health score of "GREAT."
The research firm expressed growing bullishness on Volt after observing live PFA (pulsed field ablation) case viewings of competing systems including Farapulse/Opal and Varipulse/CARTO. Oppenheimer noted that Varipulse uptake has been "subdued" despite price parity with Farapulse, describing this situation as a "head-scratcher." As a prominent player in the Healthcare Equipment & Supplies industry according to InvestingPro, Abbott’s competitive positioning is crucial for investors tracking the sector.
Oppenheimer identified two key catalysts for Abbott in the second half of 2025 that could improve the company’s performance. First, the potential Volt PMA approval could yield "significant gains" in electrophysiology if Abbott leverages pricing as a competitive advantage.
The second catalyst involves Abbott’s glucose-ketone dual sensor system, which was recently announced for integration with Tandem Diabetes Care (NASDAQ:TNDM)’s insulin pump. Oppenheimer plans to monitor presentations at the upcoming American Diabetes Association conference next week for additional insights into this technology.
The firm characterized current consensus sentiment on Abbott as "lukewarm" but believes the risk-reward profile presents "a nice setup" heading into the latter half of 2025, with potential competitive advantages emerging in the Type 1 diabetes market if Abbott successfully implements its dual sensor technology. With the stock trading near its 52-week high and showing historically low price volatility, investors can access detailed analysis and 10+ additional ProTips through InvestingPro’s comprehensive research reports.
In other recent news, Abbott Laboratories reported first-quarter earnings with a revenue of $10.36 billion and earnings per share (EPS) of $1.09, slightly missing revenue estimates but exceeding EPS forecasts. The company’s Medical (TASE:BLWV) Devices segment showed strong performance, achieving a 12.6% organic growth, while Continuous Glucose Monitoring (CGM) sales increased significantly, particularly in the U.S. market. Abbott also received FDA approval for its Tendyne transcatheter mitral valve replacement system, expanding its portfolio in minimally invasive structural heart therapies. Furthermore, Abbott announced a quarterly dividend of 59 cents per share, marking its 406th consecutive quarterly dividend. Analysts from Bernstein SocGen and TD Cowen have raised Abbott’s stock price targets to $144 and $145, respectively, with both maintaining positive ratings due to the company’s robust performance and resilience in challenging market conditions. The FreeStyle Libre CGM technology from Abbott has been linked to a substantial reduction in cardiovascular-related hospitalizations for diabetes patients, according to recent REFLECT studies. Despite some challenges in the Diagnostics division due to China’s Volume-Based Procurement policy, Abbott remains optimistic about overcoming these hurdles later in the year. The company’s ability to maintain its 2025 financial guidance amidst tariff impacts underscores its operational strength.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.